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Increasing numbers of children are surviving life-threatening childhood conditions due tomedical advances. This
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Themajority of prescribedmedications in children are administered
in an “off-label” or unlicensed manner. This means that they are pre-
scribed for either an unapproved indication, age group, formulation or
dosage due to a lack of regulatory approval tomeet the acceptable stan-
dards of efﬁcacy, safety and quality (Frattarelli et al., 2014). Paediatri-
cians therefore prescribe most medicines using the best available
evidence in the best interests of their patients. The reason for medica-
tions having to be prescribed in this manner is due to the lack of evi-
dence to inform regulatory bodies, as previously there were no
ﬁnancial incentives to undertake the necessary studies.
The pharmaceutical industry is no longer permitted to develop new
medicines for use in adults only. In 2007 the European (EU)Union intro-
duced a new regulation concerningmedicinal products that are indicat-
ed for use in paediatric populations (Hawcutt & Smyth, 2008). Parallel
legislation exists in the US (Turner, Catapano, Hirschfeld, & Giaquinto,
2014). The EU Paediatric Drug Regulation aims to encourage more
high quality ethically sound research in children and adolescents to pro-
mote the achievement of marketing authorisation in a greater number
of medicines. This was achieved through the introduction of Paediatric
Investigation Plans (PIPs), offering substantial funding incentives to
the pharmaceutical industry for contributing to paediatric pharmacolo-
gy research (van Riet-Nales et al., 2014). Pharmaceutical companies
who now complete a PIP can be rewarded with a six-month extension
to the patent of their product. Furthermore so called ‘orphan drugs’,
those that have been developed to treat a rare condition in children,
are now rewardedwith two yearsmarket exclusivity, and any off patent
drug designed for childrenwill get an eight-year data and ten-yearmar-
ket exclusivity for that indication (Paci & Vassal, 2012). Since the intro-
duction of these EU incentives, there has been an increase in the
proportion of clinical trials that include children (Turner et al., 2014).
Child-speciﬁc data is very important. Children are distinct from
adults and even differ across infancy and childhood as they are undergo-
ing extensive physiological and psychological changes during growth
and development. In children the bioavailability, volume of distribution,
metabolism and clearance of drugs differs from adults. Differences exist
in gastric pH, intestinal emptying and bile and pancreatic acids in chil-
dren together with increased total body water and alterations in mem-
brane permeability affecting drug distribution (Fernandez et al., 2011).
The hepatic blood ﬂow and metabolising enzymes are decreased with
implications for drugmetabolism; excretion is affected by the immature
glomerular ﬁltration, renal tubular secretion and tubular reabsorption
of children, especially babies. These changes are particularly true in
the younger population such as the neonate (de Wildt, Tibboel, &
Leeder, 2014), during critical illness or in children with co-morbidities
(Liborio, Branco, & Torres de Melo Bezerra, 2014). In a similar manner
to adults, drug interactions and genetic variations may also exist.
Using adult data to directly guide the use of drugs in children therefore
has its limitations, and it is for this reason that they deserve dedicated
pharmacological research using a translational approach (Fig. 1).
In addition to differences in drug handling in children, the conse-
quences of childhood drug exposure on organs including the kidney
may only become apparent once the child grows into an adult. Due to
advances in medical management, many children are now surviving
previously life-threatening conditions: for example, the survival rate
of extreme prematurity (those infants born b27 weeks gestation) has
improved from 62% to 81% over the past 20 years (Bode et al., 2009),
and death from multi-organ failure has halved (Joffe, Anton, &is article as: Oni, L., et al., Optimising the use ofmedicines to re
7), http://dx.doi.org/10.1016/j.pharmthera.2017.02.018Burkholder, 2011). Survival rates from childhood leukaemia have dra-
matically improved from 28% in 1968 to current rates of 81% (in 2005)
and 0.1% of all adults are now survivors of childhood cancer (Basta,
James, Gomez-Pozo, Craft, & McNally, 2011; Mariotto et al., 2009).
This pattern is seen in chronic disease states too: the life expectancy of
patients with cystic ﬁbrosis (CF) is now around 40 years of age
(Harness-Brumley, Elliott, Rosenbluth, Raghavan, & Jain, 2014). With
this increased survival long-term renal morbidity associated with treat-
ment in childhood is now being identiﬁed in adults. For prematurity,
childhood cancer and cystic ﬁbrosis chronic kidney disease (CKD)
in later life is now recognised (Mulder et al., 2013; Quon,
Mayer-Hamblett, Aitken, Smyth, & Goss, 2011; Rodriguez-Soriano,
Aguirre, Oliveros, & Vallo, 2005); furthermore, adult patients with CF
have an annual prevalence of CKD of over 2%. In each of these patient
groups the CKD risk is directly related to the earlier exposure of nephro-
toxic agents and perhaps even acute kidney injury (AKI) episodes. Pre-
vious studies demonstrate that even with normal baseline renal
function, a single AKI episode increases the risk of CKD by up to 1.9–
13 times (dependent on the deﬁnition of severity used)when compared
to a matched non-AKI population, even after a short follow up period
(Belayev & Palevsky, 2014). Although it should be noted that the ﬁnd-
ings described in all of these studies are merely proposed causal
associations.
Thus, it is important to note that as a consequence of medical ad-
vances, where intensive treatment with antibiotics improves outcomes
and acute organ injury can bemanaged, and as life expectancy rises, the
burden of CKD due to nephrotoxic drug exposure causing AKI in child-
hood is likely to increase. This increasing risk emphasises the impor-
tance of preventing AKI through a person-centred approach to ensure
patients obtain the best possible outcome from their medicines in a
safe and effective way. This is termed medicines optimisation (NICE,
2015). The aim of this review is to illustrate and discuss ways in
which the use of nephrotoxic medications in children could be
optimised in order to reduce AKI episodes and subsequently minimise
the long-term risk of CKD.duce acute kidney injury in children and babies, Pharmacology & Ther-
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Internationally agreed deﬁnitions of AKI exist. Due to its low cost
and ease of measurement, creatinine-based assessments of AKI are gen-
erally adopted and allow for comparison between international studies
(Askenazi, 2011). The most common creatinine-based tools used in
children are the pRIFLE (paediatric risk, injury, failure, loss and end
stage renal disease) or the acute kidney injury network (AKIN) criteria
(Akcan-Arikan et al., 2007; Mehta et al., 2007), both of which have
been modiﬁed from the original adult derived classiﬁcation to include
parameters suitable for childhood patients (Kavaz et al., 2012). Both
tools have limitations, since for example the use of creatinine in patients
with lowmuscle mass states is unreliable and their use in preterm neo-
nates is problematic. Creatinine levels in preterm neonates are much
higher than can be expected for their body size; one proposed explana-
tion for this is that the immature kidney is able to reabsorb creatinine
during the slow urinary ﬂow that occurs along immature renal tubules
(Matos, Duarte-Silva, Drukker, & Guignard, 1998). Another limitation
is the variation in measurements used in different laboratories that
will especially inﬂuence patients such as neonates who have a creati-
nine value at the lower end of the spectrum and where a difference
from 15 μmol/L to 30 μmol/Lmay represent clinical signiﬁcance. Despite
these limitations the pRIFLE and AKIN are generally accepted as the
most suitable tool for the classiﬁcation and comparison of AKI in
children.
1.2. Incidence of drug-induced AKI in children
AKI is thought to occur in up to 30% of children in intensive care
(Faught, Greff, Rieder, & Gideon, 2014). In all types of AKI, prescribed
medications are the causative agents in N25% of patients (Bentley,
Corwin, & Dasta, 2010). The majority of drug-induced AKI episodes
are due to non-steroidal anti-inﬂammatory drugs (NSAIDs), antibiotics
or chemotherapeutic agents. Children receiving these drugs are typical-
ly acutely unwell and thus they will have confounding factors, such as
hypovolaemia, hypotension, that increase their propensity to develop
AKI. One of the most common classes of nephrotoxic antibacterial
drugs used in children is the aminoglycosides (Sinclair et al., 2014).
Around 20–30% of all children treated with an aminoglycoside for
N5 days develop AKI (Zappitelli, Moffett, Hyder, & Goldstein, 2011). A
study assessing 175 children with previously normal renal function,
demonstrated that after 48 h of vancomycin treatment AKI occurred
in 14% of patients and was related to the dose used, the length of thera-
py and the additional use of concomitant drugs (Sinclair et al., 2014).
Our in-house data (unpublished, courtesy of author DH) has demon-
strated that over a two-year period from December 2009 to November
2011, 754 children received treatment with aminoglycoside antibiotics
at AlderHey Children's NHS Foundation Trust, Liverpool, UK. Sixty-three
children (8.4% of those treated) developed AKI (deﬁned by the AKIN
criteria) during or shortly after treatment, and21 (2.8% of those treated)
had severe AKI (AKIN stage 2 or 3). Obviously in a tertiary care setting
AKI may be multifactorial but this data demonstrates that AKI is a com-
mon, often severe, clinical condition seen in everyday practice.
2. Pathophysiology of nephrotoxic AKI
Understanding the mechanism leading to AKI is crucial to develop-
ing improvedmethods of detection or novel treatment options in the fu-
ture. The kidney is exposed to a large number of drugs because it
receives one quarter of cardiac output. Drug-induced AKI typically in-
volves renal tubular cells as they exist in a predominantly hypoxic envi-
ronment in order to cope with the high metabolic demands required in
the day to day task of management of electrolyte reabsorption and con-
trolling hydration. The proximal renal tubules are presentedwith highly
concentrated drugsmaking themparticularly vulnerable to injury.More
speciﬁcally, drugs can either have the requisite charge and size forPlease cite this article as: Oni, L., et al., Optimising the use ofmedicines to re
apeutics (2017), http://dx.doi.org/10.1016/j.pharmthera.2017.02.018ﬁltration at the glomerulus or be taken up by the apical membrane of
the renal tubular cells or transported across the basolateral membrane
through transporters such as the human organic anion transporter
(OAT) and the human organic cation transporter (OCT). Both OATs
and OCTs transport drugs including tenofovir or cisplatin, respectively,
and thus increase the risk of injury in the proximal tubules and adjacent
tissues (Perazella, 2009). Biotransformation of drugs also produces local
metabolites and reactive oxygen species (ROS), that can cause cytoplas-
mic accumulation and local toxicity with ultimate necrosis or apoptosis
of the renal tubular cells (Izzedine, Launay-Vacher, & Deray, 2005).
Thus, the pathophysiology of drug-induced AKI varies according to the
individual drug. Here, we shall focus on the main drugs responsible
for AKI in children. These include: NSAIDs, antibiotics (mainly the ami-
noglycosides) and immunosuppressant and chemotherapeutic agents
(mainly calcineurin inhibitors, ifosfamide, cisplatin) (Misurac et al.,
2013). In some patients the diagnosis or likely causative agent may
not always be that obvious.
2.1. Non steroid anti-inﬂammatory drug-induced AKI
The predominant NSAID prescribed in paediatric practice (Misurac
et al., 2013) is ibuprofen, a widely available and commonly used drug
in children as a simple analgesic, antipyretic or anti-inﬂammatory
agent. In addition, ibuprofen is often used in neonates in an attempt to
close a patent ductus arteriosus. NSAIDs are believed to have two
main AKI mechanisms. Firstly, they can insult the kidney by altering
the renal haemodynamic status, and secondly, they can cause acute tu-
bular interstitial nephritis (TIN). NSAID agents reduce cyclooxygenase
(COX) activity. In health, COX activity causes vasodilation throughout
the body, including in the afferent glomerular arteriole, by the synthesis
of prostaglandin PG (predominantly PGE2 and prostacyclin). The
NSAIDs therefore cause vasoconstriction as a result of decreased prosta-
glandin production arising from COX suppression. In normovolaemic
and normotensive children the vasoconstrictor effect of NSAIDs is un-
likely to cause signiﬁcant vasoconstriction and/or reduced renal perfu-
sion. However, in a child who is intravascularly deplete, for example
due to acute gastroenteritis, the vasoconstrictor effect can lead to the
development of AKI by reducing renal perfusion, increasing hypoxia
and subsequently causing acute tubular necrosis (ATN) of varying de-
gree. The second method of injury is TIN since NSAIDs are responsible
for 20% of all cases of TIN (Valluri et al., 2014). Acute TIN occurs as the
pathways responsible for the breakdown of arachidonic acid are
disrupted due to NSAID-induced COX inhibition, resulting in the local
production of leukotrienes that can cause a local inﬂammatory response
within the tubulointerstitium.
2.2. Aminoglycoside induced AKI
Antibiotics, mainly the aminoglycosides (AG) such as gentamicin,
amikacin and tobramycin, are nephrotoxic (Wargo & Edwards, 2014).
AG-induced nephrotoxicity is characterized by selective targeting of
proximal tubule cells. Accumulation of the drugwithin the proximal tu-
bule cells, is thought to be the key determining mechanism for the de-
velopment of toxicity (Mathews & Bailie, 1987). Endocytosis via the
multi-ligand receptor megalin has been demonstrated to be the princi-
pal pathway for this accumulation. This is supported by the fact that
megalin knock-out mice do not exhibit renal accumulation of AGs
(Schmitz et al., 2002). Intracellular aminoglycoside can result in apopto-
sis or necrosis of proximal tubule cells by a variety of pathways (mito-
chondrial dysfunction and the release of reactive oxygen species)
(Servais et al., 2005; Servais et al., 2008). AG-induced nephrotoxicity
is described as non-oliguric renal failure with a varying degree of renal
tubular dysfunction (Begg & Barclay, 1995). A reduction in GFR is re-
ported to be a late event, occurring between 5 and 10 days after the
start of treatment (Taber & Pasko, 2008). The renal impairment is re-
ported to be completely reversible in most patients upon earlyduce acute kidney injury in children and babies, Pharmacology & Ther-
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tion that repeated episodes of AKI or AG exposure may contribute to
later chronic damage (Belayev & Palevsky, 2014).
2.3. Immunosuppressant and chemotherapy induced AKI
The main nephrotoxic immunosuppressive agents are the calcine-
urin inhibitors (CNI's) that are used for solid organ transplantation
and contribute to vascular dysfunction resulting from an increase in va-
soconstrictor factors, endothelin and thromboxane, and activation of
the renin-angiotensin system (RAS). A reduction of vasodilator factors
prostacyclin, prostaglandin E2, and nitric oxide (NO) also occurs togeth-
er with free radical formation and sympathetic nerve activation. Finally,
reversible tubular dysfunction is recognised as a feature of acute CNI
nephrotoxicity. The two most common CNI agents, ciclosporin and ta-
crolimus, which have a completely differentmolecular structure and in-
tracellular binding site but a similar toxicity proﬁle, suggest that these
effects are related to calcineurin/NFAT-dependent mechanisms
(Naesens, Kuypers, & Sarwal, 2009).
There are many chemotherapeutic agents that can cause kidney in-
jury. The most commonly prescribed in children are ifosfamide and cis-
platin. Ifosfamide is a nitrogen mustard-alkylating agent which is
metabolised by the enzyme CYP3A into chloroacetaldehyde; it affects
both the glomerulus and renal tubules and causes proximal tubular dys-
function in all patients and AKI in up to 30% of children (Knijnenburg
et al., 2013); this incidence is greater than in adult equivalent cohorts
(Oberlin et al., 2009; Skinner et al., 2010). Younger children seem to
be at a particular risk. One explanation for this may be due to the higher
expression of hepatic CYP3A in the younger population (Aleksa,
Halachmi, Ito, & Koren, 2004; Aleksa et al., 2005), ifosfamide is
metabolised by CYP3A producing toxic levels of chloroacetaldehyde.
This leads to a cascade of events, where the proximal renal tubular
cells undergo oxidative stress, followed by impaired solute reabsorption
and cell necrosis, and subsequently a depletion of glutathione. The kid-
ney is dependent on glutathione to maintain its redox status and thus
inﬂuences susceptibility to cytotoxicity induced by oxidants and elec-
trophiles (Lash, 2005). Cisplatin is believed to contribute to nephrotox-
icity through a completely differentmechanism,which occurs following
its uptake by the basolateral OCT, hence uptake from the blood stream.
It primarily targets DNA, producing ROS and activating signalling path-
ways such as the mitogen-activated protein kinase (MAPK), P53 and
P21. Local proximal tubule cell death occurs togetherwith an inﬂamma-
tory response from the production of tumour necrosis factor (TNF)-
alpha and TNF-alpha receptor 2 (Hanigan & Devarajan, 2003). The over-
whelming oxidative stress response appears to be the damaging insult
to the kidney in cisplatin nephrotoxicity.
Despite differing pathophysiological mechanisms of injury, using
nephrotoxic agents in combination increases the risk of developing
AKI. Additionally, existing renal insufﬁciency, prolonged therapy, high
drug concentrations and dehydration can increase this risk further.
3. Patient susceptibility to drug-induced AKI
3.1. Host factors
Host factors can inﬂuence the risk of developing nephrotoxicity,
explaining the variability often seen in its occurrence. In adults, females
are at a greater risk of drug-induced AKI when compared to males due
to their reduced body size and reduced total bodywater volume. Under-
estimation of GFR also occurs in females due to a lower mean body
weight and lack of recognition of creatinine changes from a baseline
that may be lower than that of males. Gender differences in the activity
of cytochrome P450 and uridine diphosphate glucuronosyltransferase
(UGT) enzymes result in differences in the drug clearance (Anderson,
2008). Accurate drug dosing is made difﬁcult by the complexities of
changing body size, underestimation of GFR and body compositionPlease cite this article as: Oni, L., et al., Optimising the use ofmedicines to re
apeutics (2017), http://dx.doi.org/10.1016/j.pharmthera.2017.02.018during growth combined with changing enzyme expression levels and
a lack of reliable pharmacokinetic (PK) data These all contribute to the
risk of AKI (de Wildt et al., 2014). Preterm infants born before
34 weeks gestation are at particular risk of AKI as the kidney is still de-
veloping new nephrons, with fetal nephrogenesis not being completed
until 34–36weeks gestation. Offsetting this however, neonatesmay not
have some of the other risk factors described above as the concentrating
ability of the neonatal tubules is poor and energy-dependent processes
are less prominent. Therefore the preterm neonate especially those
born at the limits of viability, represent a complex childhood population
in terms of drug handling and toxicity (Kent, Turner, Sharland, & Heath,
2014; Zaffanello et al., 2010). Maternal health during pregnancy may
also affect in utero nephrogenesis for the child, for example babies ex-
posed to poor nutrition or infants of diabetic mothers may have fewer
nephrons and thus be more susceptible to kidney injury (Benz &
Amann, 2010; Gross, Amann, & Ritz, 2005).
Other patient susceptibility factors include speciﬁc disease states, for
example volume depletion due to intercurrent illness, a low circulating
plasma albumin, liver cirrhosis, obstructive jaundice and pre-existing
acute or chronic kidney disease (Perazella, 2009).
3.2. Pharmacogenomics
Predicting how an individual may respond to a particular drug is
possible through the appropriate use of pharmacogenomics, which
can explain some of the person speciﬁc variability. Pharmacogenomics
is a method of explaining the individual pharmacodynamic and PK
drug responses and how they differ according to a patient's genotype.
It is estimated that 10–20% of ADRs are genetically determined
(Ingelman-Sundberg, 2004). A good example of the use of
pharmacogenomics is through the identiﬁcation of genes that cause
tenofovir-induced renal Fanconi syndrome. In patients exposed to
tenofovir, a single nucleotide polymorphism was found to be present
in the gene encoding the multidrug-resistant protein-2 (MRP2) efﬂux
transporter in those who developed Fanconi syndrome. This gene is
usually responsible for transporting tenofovir out of the cell (Izzedine
et al., 2006). Therefore, testing for this genotype prior to treatment
may identify patients at risk of developing its nephrotoxic adverse ef-
fects. Within our Centre, the search for genes responsible for cisplatin
and AG induced renal tubular damage is currently underway
(Hawcutt, 2011).
4. Consequences of drug-induced AKI
It has been recognised that the presence of AKI, of any aetiology, in-
dependently correlates acutely with a longer hospital stay, with greater
mortality and in the long-term, a worse renal outcome (Askenazi,
2011). The acute complications are mainly associated with the ﬂuid
overload resulting fromAKI and in the longer term, incomplete renal re-
covery or accelerated progression to CKD.
Due to the increase in overall life expectancy, the kidney is a suscep-
tible organ to the impact of co-morbidities, such as diabetes and ischae-
mic vascular disease; therefore CKD is emerging as an important
healthcare problem in the general population (Imran et al., 2015). As
many patients with drug-induced AKI have additional co-morbidities,
it is difﬁcult to determine the precise long-term risk of CKD from use
of the drug in question. However, in a large study by Goldstein's
group, 70% of children who were exposed to either N3 days of AG or
N3 nephrotoxic agents, and who developed AKI, demonstrated features
of residual kidney damage as early as 6 months post AKI (Menon,
Kirkendall, Nguyen, & Goldstein, 2014). Longer-term studies are re-
quired to conﬁrm these ﬁndings, however, this is in keeping with the
earlier described studies on the cumulative effect of AG in patients
with CF. Reducing the long-term consequence of kidney injury and in-
ﬂammation associated with drugs administered during childhood is
therefore an important healthcare priority.duce acute kidney injury in children and babies, Pharmacology & Ther-
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5.1. Current management
The current detection of AKI is based on serum creatinine, urea and
urine output, with the mainstay of management being supportive care
and reducing any further renal insults. National initiatives are in place
to enhance the early detection of AKI and include reporting estimated
GFR values andmethods to alert clinicians to rising creatininemeasure-
ments (England, Date accessed 20.6.15). Whilst these are more compli-
cated to introduce in a childhood population due to variations in the
creatinine values according to age and body size, strategies have been
developed to overcome this.
In general, management should involve;
• Identiﬁcation
• informing the patient
• reducing further nephrotoxic insults
• assessing and supporting adequate hydration
• identifying the need for senior and/or specialist input (e.g.: nephrolo-
gist review)
• monitoring electrolytes to initiate renal replacement therapy if re-
quired
• ensuring resolution of renal function
• screening for risk factors for CKD (hypertension and proteinuria).
In drug-induced renal inﬂammation such as acute TIN, a short course
of oral corticosteroids may improve the renal outcome, however, the
supporting evidence is weak, and robust clinical trials are needed
(Gonzalez et al., 2008).
5.2. Prevention of AKI
Avoidance, cautious and/or judicious use of nephrotoxic agents
could help to reduce or prevent drug-induced AKI, although in clinical
practice this is often challenging. Othermethods include using extended
dosing intervals and short-term therapy with adequate therapeutic
monitoring.
5.2.1. Optimal dosing
Although there has been an improving trend since the introduction
of the EU regulation on the use of paediatric drugs in 2007, there re-
mains a signiﬁcant paucity of appropriate information to guide the op-
timal medication dosing in infants and children. A priority in drug
administration is to adjust for the patients eGFR and in cases of AKI to
adjust this on a daily basis. Guidance on appropriate drug dosing in pa-
tients with established renal impairment is difﬁcult to ﬁnd and limited,
this is especially true in the cohort of childrenwhoare exposed tomulti-
organ supportive measures as part of intensive care management. PK
data in neonates demonstrate variability according tomaturity, postna-
tal age and adjunctive medications (De Cock et al., 2012; Vucicevic,
Rakonjac, Miljkovic, Jankovic, & Prostran, 2014). Furthermore, there is
very little guidance on how to dose many drugs used in children or ne-
onates who undergo extra-corporeal membrane oxygenation (ECMO),
continuous veno-venous haemoﬁltration, haemodialysis or acute peri-
toneal dialysis. A recent study has demonstrated that modes of dialysis
inﬂuence the clearance of drugs that are not even metabolised by the
kidney, through alteration of hepatic enzyme levels (Thomson et al.,
2015). In each of these situations the kidney is already insulted; there-
fore, minimising further harmwhilst achievingmaximum drug efﬁcacy
to increase the chance of overall recovery is a clinical conundrum,which
emphasises the importance of speciﬁc PK studies in children of differing
ages but also in differing circumstances. This is an overwhelming chal-
lenge driving the need to design multi-centre studies due to the small
number of eligible patients and the severity of their illness.Please cite this article as: Oni, L., et al., Optimising the use ofmedicines to re
apeutics (2017), http://dx.doi.org/10.1016/j.pharmthera.2017.02.0185.2.2. Pharmacovigilance
Monitoring the pharmacovigilance of drugs after their licensed use is
an important aspect of ensuring safety. Reporting and recording adverse
drug events through local and national systems should be a routine part
of clinical care, although under-reporting is common (Hawcutt,
O'Connor, & Turner, 2014). In the UK, the MHRA Yellow Card system
provides a unitedway ofmonitoring drug safety, with themedian num-
ber of ADRs reported per annum between 2000 and 2009 in children
being 2146 (Hawcutt, Mainie, Riordan, Smyth, & Pirmohamed, 2012).
Encouragingly, reports of drug-induced nephrotoxicity and electrolyte
disturbances have been detected through such reporting systems, thus
highlighting their role in the longer-term monitoring of medications
(Ramirez, Jimenez, et al., 2013; Ramirez, Rossignoli, et al., 2013; Riva
et al., 2013).
5.2.3. Improved detection of AKI
AKI is currently detected late in the disease process. In case an obvi-
ous precipitating agent fails to be identiﬁed, the optimal method of de-
termining the extent of AKI is by renal biopsy. However, this is rarely
undertaken as the risks are likely to be greater than the beneﬁts, and a
clinical history, together with renal symptoms or signs, may assist
with determining the probable cause.
Recent studies have demonstrated that the establishment of novel
biomarkers allows an earlier detection of renal injury (Fuchs & Hewitt,
2011; Khan, Batuman, & Lertora, 2010). Themost promising biomarkers
in all forms of childhood AKI incorporate clinical propensity scoring,
perhaps highlighting the multifactorial aetiology (Constance et al.,
2016; Menon et al., 2016). Our group have undertaken proof-of-
concept studies to investigate the role of biomarkers in detecting AG
nephrotoxicity in neonates (McWilliam et al., 2012). The most promis-
ing biomarkers to be discovered in the earlier detection of drug-induced
AKI are cystatin C, kidney injury molecule-1 (KIM-1), neutrophil
gelatinase associated lipocalin (NGAL), N-acetyl-B-D-glucosaminidase
(NAG) and low molecular weight proteins such as B2 microglobulin
and retinol binding protein (RBP) (Fuchs & Hewitt, 2011; Khan et al.,
2010). Table 1 summarises their mechanism of release and the type of
drug injury they detect. Most of these biomarkers are more accurately
measured in the urine as this likely represents the kidney better than
blood concentrations. None of these biomarkers have yet to be routinely
measured within the clinical setting but reference intervals for children
(for KIM-1 and NGAL) are reported (McWilliam et al., 2014). Members
of our group have been actively involved in the qualiﬁcation of a num-
ber of these urinary biomarkers for use in children (McWilliam et al.,
2012; McWilliam et al., 2014).
Healthcare alerts using electronic triggers to identify high-risk pa-
tients may reduce the incidence of nephrotoxic AKI, by allowing better
recognition and earlier intervention (Kirkendall et al., 2014). These sys-
tems can be passive, interrupted (requiring an action to the prompt) or
active, such as where an early intervention team are activated (Thomas
et al., 2015). Those with active interventions are believed to bemore ef-
fective and avoid clinician ‘alert fatigue’ that may occur with electronic
systems. An electronic system developed to identify patients at high-
risk of nephrotoxicity has been described in the literature, detailing
that the system sends emails to the appropriate nephrologist with key
clinical information (Kirkendall et al., 2014). Other methods to detect
established AKI earlier include measuring daily serum creatinine levels
in patients at risk (Downes et al., 2015; Zappitelli et al., 2011). In a
study assessing N100 children with CF who received intravenous AG
for N3 days, daily serum creatinine measurement promoted earlier de-
tection of AKI but did not prevent its onset (Downes et al., 2014).
5.2.4. Drugs that induce biological systems
Understanding the pharmacology of drug toxicity allows the use of
novel methods to prevent drug-induced AKI through the manipulation
of biological pathways that directly contribute to kidney injury. Many
of these methods use drug repurposing i.e.: using a drug alreadyduce acute kidney injury in children and babies, Pharmacology & Ther-
Table 1
Biomarkers associated with drug-induced kidney injury.
Urinary
biomarker
Source Mechanism of release Drugs
Kim-1 Urine Expressed by tubular epithelial cells in response to injury Cisplatin, aminoglycosides, ciclosporin
Cystatin C Blood Expressed by nucleated cells, inhibitor of extracellular cysteine proteinase, glomerular ﬁltration,





Urine Found in all nucleated cells, glomerular ﬁltration, reabsorption by proximal tubular cells Aminoglycosides, cisplatin, tenofovir
NGAL Urine Protein that belongs to the lipocalin family and is expressed by the tubules during injury Aminoglycosides, cisplatin, ciclosporin,
radiocontrast dye
NAG Urine Proximal tubular lysosomal enzyme, increased expression in injury Ciclosporin, tacrolimus, aminoglycosides,
cisplatin
RBP Urine Synthesised in the liver and ﬁltered by the glomerulus, reabsorbed by proximal tubular cells Aminoglycosides, cisplatin, tenofovir
Abbreviations: Kim-1, kidney injury molecule 1; NGAL neutrophil gelatinase associated lipocalin; IL interleukin; NAG N-acetyl-B-D-glucosaminidase; RBP retinol binding protein.
6 L. Oni et al. / Pharmacology & Therapeutics xxx (2017) xxx–xxxavailable for a different purpose. This has the advantage of gaining
more market opportunities for the pharmaceutical manufacturer. A
good example of this is the combined use of phenytoin as an enzyme
inducer, with corticosteroids to induce p-glycoprotein since both
drugs have been shown to synergistically reduce tacrolimus nephro-
toxicity (Bax, Tijssen, Rieder, & Filler, 2014). Another example cur-
rently being evaluated is the inhibition of the mevalonate pathway
using statins to prevent AG nephrotoxicity by reducing renal tubular
cell cytotoxicity (Antoine, Srivastava, Pirmohamed, & Park, 2010).
The translation of these strategies into clinical practice is currently
underway in children with CF by some of our authors. It has also
been speculated that N-acetylcysteine (NAC) is able to prevent
ifosfamide toxicity and clinical trials in this area are awaited (Hanly
et al., 2012).5.3. Novel treatments under evaluation
In patients with established AKI, cell-based regenerative medicine
therapies offer a potential avenue for regeneration and repair of the
damaged kidneys. In preclinical studies and phase 1 clinical trials, the
administration of mesenchymal stem/stromal cells (MSC) to subjects
with AKI led to signiﬁcant improvements in renal health and renal func-
tion in rodents, especially when delivered intra-arterially (Wang, He,
Pei, & Zhao, 2013). However, despite these beneﬁcial effects, there are
a number of safety issues associated with MSC therapy that need to be
addressed. For instance, in animal models, MSCs have been shown to
promote tumour growth (Djouad et al., 2003), generate sarcomas
(Tasso et al., 2009), and form inappropriate cell types within the kidney
(Kunter et al., 2007). A further concern is that the cells could cause intra-
vascular thrombosis, as shown in a recent study where high doses of
MSCs caused deterioration of renal function in rodents (Cai et al.,
2014). The importance of deﬁning the correct dose is further highlight-
ed by the Phase 2 trial ‘ACT-AKI’ (NCT01602328) that evaluated MSCs
for the treatment of AKI in cardiac bypass patients. In this trial, out-
comes were worse in patients who received the therapy (Gooch &
Westenfelder, 2016; Swaminathan et al., 2014), and this was likely
due to the cells forming microthrombi within the renal vasculature.
The therapeutic effects of MSCs, and indeed many other cell types, in-
cluding kidney-derived cells (Bruce et al., 2015) and renal progenitor
cells (Toyohara et al., 2015), aremediated by paracrine factors that sup-
press inﬂammation, promote tubular cell proliferation and prevent ap-
optosis (Geng et al., 2014; Sharkey et al., 2016). There is evidence to
suggest that some of these effects are mediated by extracellular vesicles
(EVs) (Bruno et al., 2009) modulating the immune system (Robbins &
Morelli, 2014). Our increasing understanding of the mechanisms
whereby cell therapies elicit their beneﬁcial effects will facilitate the de-
velopment of safer and more effective therapies in the future; for in-
stance, the administration of EVs rather than the cells themselves
would circumvent the potential risks of tumourigenesis, mal-
differentiation and thrombosis.Please cite this article as: Oni, L., et al., Optimising the use ofmedicines to re
apeutics (2017), http://dx.doi.org/10.1016/j.pharmthera.2017.02.0186. Conclusion
Drug-induced AKI is a serious problem in children especially those
who are now surviving previously life-threatening diseases and in
whom we aspire to a life expectancy that matches the general popula-
tion with minimum co-morbidity. Avoiding these drugs completely is
impractical, rather innovative methods to inhibit or detect the conse-
quences of these agents should be prioritised. An awareness of the
mechanism of nephrotoxicity of these drugs is important as it facilitates
understanding of novel biomarkers and allows exploration into poten-
tial adjuncts to combat the toxicity. Due to the healthcare costs and con-
sequences associated with drug-induced AKI, it is likely that these
strategies will become a part of routine prescribing in the future.Conﬂict of interest statement
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